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Introduction: Current investigation for patients with colorectal symptoms without overt rectal bleeding is
undertaken by colonoscopy or by ﬂexible sigmoidoscopy and barium enema. A large majority of patients
do not have colorectal cancer. There exists no instant, objective measure to discriminate patients who are
likely to have colorectal cancer and therefore require expedient investigation.
Aim: To evaluate the sensitivity and speciﬁcity of immunological faecal occult blood testing (FOBT) in
patients with colorectal symptoms without overt rectal bleeding.
Methods: Consecutive patients referred for urgent colonic investigation, were prospectively studied. A
faecal sample was obtained from each one and subjected to immunological FOB which tested either
negative or positive. All patients then underwent complete colonic imaging. The correlation between
FOBT status and results from colonic imaging was studied.
Results: Of 126 tested, thirty patients (26.8%) were FOBT positive. One hundred and twelve patients
underwent complete colonic imaging. In the FOBT positive group colonic imaging identiﬁed 17 cases of
histologically proven adenocarcinoma, 1 recurrent squamous cell carcinoma of anus, 1 adenomatous
polyp, 6 cases of diverticulosis, and no pathology in 5 cases. In the 82 FOBT negative patients, no cancers
were found. Overall the Immunological Faecal Occult Blood Test was found to have 100% sensitivity and
86.3% speciﬁcity.
Conclusion: Immunological faecal occult blood testing is a sensitive and speciﬁc test in identifying
colorectal cancer and may be useful in identifying those patients who warrant urgent investigation.
Routine clinical application may be useful in the allocation of resources.
Crown Copyright  2013 Published by Elsevier Ltd on behalf of Surgical Associates Ltd. All rights
reserved.1. Introduction
Colorectal cancer is the second most common cause of cancer
death in the UK. With an annual incidence of 34,000, it results in
16,000 deaths per annum.1 Despite advances in diagnosis, surgical
treatment and adjuvant chemotherapy, survival has remained
largely unchanged over the last decade. The majority of colorectal
cancer is sporadic and it is the early detection and removal of these
lesions that correlates with a favourable outcome.2e7
In the United Kingdom, ‘rapid access’ colorectal clinics exist for
assessment of patients suspected of having colorectal cancer.8 It is
recognised, however, that 85e90% of those referred have non
malignant, if any, colonic pathology. Despite this fact, all patients
are referred for further investigation on an urgent basis. At present,fe).
013 Published by Elsevier Ltd on bno means of stratiﬁcation exists to identify those patients who are
likely to be harbouring colorectal cancer, therefore allowing tar-
geted and timely use of valuable resources.
In this prospective cohort study we examine the sensitivity and
speciﬁcity of an immunological faecal occult blood test (FOBT) in
the detection of colorectal cancer in symptomatic patients in the
absence of overt rectal bleeding.
2. Aim
To evaluate the sensitivity and speciﬁcity of immunological
faecal occult blood testing (FOBT) in patients with colorectal
symptoms without overt rectal bleeding.
3. Methods
Following approval from the regional ethics committee, all consecutive con-
senting patients attending the rapid access colorectal service were prospectivelyehalf of Surgical Associates Ltd. All rights reserved.
Table 1
Correlation of FOBT results with colonic pathology identiﬁed.
FOBT positive FOBT negative
Adenocarcinoma 17 0
Squamous cell carcinoma 1 0
Adenomatous polyp 1 4
Diverticulosis 6 45
Crohns 0 1
Solitary rectal ulcer 0 1
No pathology 5 31
30 82
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titioner, were recorded. Patients reporting recent or ongoing overt rectal bleeding
were excluded from the study.
Stool samples, without dietary or medicinal restriction, were obtained either
prior to clinic visit or during per rectal examination. Samples were then tested using
the immunological FOBT (OC-Light ‘Eiken’, Nagase, Japan) as previously described.9
This test utilises an immuno-chromatography technique to detect intact human
haemoglobin and is sensitive to a level of 40 ng/ml. All tests were performed by a
consultant surgeon trained in the procedure. Quality control was ensured by random
rechecking in 10% of samples. The collected stool was sampled using a small, spiral
rod supplied with the test kit. This was then returned to and mixed vigorously with
the reagent for 30 s and the chromatography strip placed in the resulting solution. A
single, distal transverse line indicated a negative result, while a double line indicated
a positive result. The test result was available within minutes.
Patients were accordingly categorised as FOBT negative or FOBT positive. Colonic
imaging was obtained in all patients irrespective of the FOBT result, and the ﬁndings
correlated with FOBT results. Colonic imaging modalities included Colonoscopy,
Flexible sigmoidoscopy, Barium enema, CT colography or combinations thereof. All
tests were performed by qualiﬁed personnel who were blinded to the results of the
FOBT test. Statistical analysis was undertaken using the ManneWhitney U test and
Chi-square analysis.
4. Results
One hundred and twenty six consecutive patients underwent
immunological FOBTovera12monthstudyperiod. Complete colonic
imaging was obtained in 112 patients; 51 male and 61 female. The
age range was from 34 to 87 years with a median of 66 years.
Sixty seven patients (59.8%) underwent sigmoidoscopy in
combination with barium enema, 37 (33%) had colonoscopy, 5
(4.5%) had barium enema alone. Three patients proceeded to CT
following failed endoscopic intubation due to obstructing cancers.
Of 112 patients undergoing complete imaging, 30 patients
(26.8%) tested as FOBT positive. Sixteen were male and 14 female;
median age 66 years, range 34e87 years. Of these, 17 were found to
have adenocarcinoma, 1 had recurrent squamous cell carcinoma of
the anus, 6 had diverticulosis, 1 had adenomatous polyp and in 5
cases no colonic pathology was found.
In the 82 patients (35 male, 47 female; median age 66 years and
range 40e82 years) identiﬁed as FOBT negative, no colorectalPatients Referred (126)
Freq (%) PV (%)
Right sided abdominal mass 7 5.6 28.6
Palpable rectal mass 2 1.6 50.0
Iron deficiency 17 13.5 41.2
CIBH < 60 plus rectal bleed 14 11.9 6.7
Rectal bleed >60 2 1.6 50.0
CIBH >60 68 61.9 11.5
PV – Predictive value of each symptom for cancer
Proximal cancer – those appearing proximal to splenic flexure, Dis
CIBH – change in bowel habit
Fig. 1. Correlation between referring symptomcancers were found. No demographic differences were identiﬁed
between groups tested. Colonic pathology and FOBT results were
correlated as shown in Table 1.
Eighteen Adenocarcinomas were found in 17 patients, with one
patient having synchronous disease in transverse colon and rectum.
All cancers were identiﬁed as FOBT positive prior to imaging.
Resection was performed in 14 patients. Duke’s staging of resected
tumours showed: 1 stage A, 5 stage B, 5 stage C and 3 stage D.
The distribution of cancers is shown in Fig. 1.
The sensitivity of immunological FOBT for colorectal cancer
was 100% with a speciﬁcity of 86.3%. Positive predictive value for
cancer was 56.6% and the negative predictive rate was 100%. Of the
126 patients referred under the 2 week rule, 8 met 2 criteria and
the remaining 118 patients were referred on the basis of a single
symptom.
The most common referring complaint in 61.9% was that of
change in bowel habit (CIBH) over the age of 60 years. Of these pa-
tients,11.5%were subsequently found to have cancer. Rectal bleeding
in patients over 60 years and presence of palpable rectal mass were
the least common reasons for attendance (1.6%). They were, how-
ever, the strongest predictors of the presence of cancer and indeed
this was increased when combined with a positive FOBT result.
Iron deﬁciency anaemia was a common symptom suggestive of
cancer, and more speciﬁcally associated with proximal lesions. All
patients reporting anaemia who subsequently tested as FOBT
positive were found to have proximal colorectal cancer. Similarly a
palpable rectal mass, change in bowel habit in patients over 60
years with rectal bleeding, and rectal bleeding in patients over 60
years were suggestive of distal cancers.5. Discussion
Colonic cancers result in occult or overt rectal bleeding. In the
detection of occult bleeding, conventional guaiac based tests rely
on the pseudo-peroxidase activity of the haem entity to generate a
positive result. The test, however, is not speciﬁc for human hae-
moglobin, may cross react with plant peroxidases and is not limited
to blood loss from the colon. Accordingly, with more than half of
cancers present being missed, it is not useful as a predictive tool
within this setting.10
In contrast, immunological FOBT is an instant and objective test
which utilizes immuno-chromatography to detect occult blood loss
in stool. It is speciﬁc to human haemoglobin and only reacts with
the intact haemoglobin molecule. It therefore requires no dietary
restriction and it only identiﬁes pathology limited to the colon. In
addition, testing may be performed on a single stool sample and
integrated into the clinical examination providing an instant resultCancer (17)
FOBT positive (30) Proximal (8) Distal (9)
freq (%) PV (%) freq PV (%) freq PV (%)
3 10.0 66.7 1 50 1 50
1 3.3 100.0 0 0 1 100
7 23.3 100.0 7 100 0 0
3 10.0 33.3 0 0 1 100
1 3.3 100.0 0 0 1 100
18 60.0 50.0 2 22.2 7 77.7
tal cancer – those appearing distal to splenic flexure
s, FOBT results and position of cancers.
Table 2
Distribution of cancers identiﬁed.
Site of cancer Frequency
Caecum 4
Ascending colon 3
Transverse colon 1
Descending colon 1
Sigmoid colon 3
Rectum 5
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it is a simple and inexpensive (1GBP) test to perform.
In this prospective studywe have shown immunological FOBT to
have a sensitivity of 100%; that is all cancers tested positive prior to
colonic imaging. Moreover, this was achieved whilst minimising
the number of false positive results generated (86% speciﬁcity).
Although we have been the ﬁrst to study it in this context, our
ﬁndings are in accordance with other studies examining the use of
immunological FOBT in other western populations.11e13
Patients with a negative FOBT still require imaging of the entire
colon. However, with cancer unlikely, these can be performed on a
non urgent basis. Furthermore a negative result may well inﬂuence
the choice of modality used to image the colon (radiological vs
endoscopic). With cancer less likely and a shift in the risk/beneﬁt
ratio, colonoscopy must be used judiciously due to inherent
morbidity and mortality associated with the procedure.14,15
In this series, 14 patients failed to undergo complete colonic
imaging as dictated by the clinical ﬁndings, therefore closely
reﬂecting true clinical practice. Three patients were lost to follow-
up, 3 failed to keep return appointments with presumed resolution
of symptoms, 1 had antibiotic related colitis, 1 with upper GI pa-
thology, 1 threadworm infestation, 2 awaiting further investigation
and 3 deemed unﬁt and under ongoing surveillance. All of these
patients had tested as FOBT negative and all had ﬂexible sigmoid-
oscopy which failed to reveal sinister pathology.
Five adenomatous polyps were identiﬁed, one of which tested as
FOBT positive. All polyps were biopsy proven, less than 10 mm and
showed low grade dysplasia. From these results immunological
FOBT shows poor sensitivity and speciﬁcity for identiﬁcation of
adenomatous polyps at 20% and 85% respectively.
Analysis of the referring symptoms identiﬁed 13 (10%) patients
that were referred inappropriately, that is, they failed to meet any
of the speciﬁed criteria, yet they were seen and investigated
consuming valuable time and resources.
The inappropriate use of the rapid access service, in combina-
tion with an ageing population and recent endorsement of a na-
tional screening programme for colorectal cancer16 will place even
more pressure on an already overstretched endoscopy service.
These factors simply serve to underline the importance of priori-
tisation and targeting of the ﬁnite resources available. At present
there exists no test to further discriminate those patients who are
likely to be harbouring colorectal cancer and therefore in need of
expedient investigation.In this prospective study we have shown that, immunological
FOBTmay offer a powerful discriminatory tool to identify colorectal
cancer from other non malignant conditions. Routine clinical
applicationmay be used to target resources at thosemost in need of
urgent investigation.
A shortcoming of this study is that the numbers studied are
small; this can be addressed by carrying out a larger multi centre
study to evaluate this before any recommendations are made
(Table 2).
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